Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Denali Therapeutics (NASDAQ:DNLIGet Free Report) had its target price upped by Jefferies Financial Group from $40.00 to $45.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Jefferies Financial Group’s price target suggests a potential upside of 66.85% from the company’s previous close.

A number of other research analysts have also recently weighed in on DNLI. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, September 4th. Wedbush lowered their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. JPMorgan Chase & Co. reduced their price objective on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. Finally, Bank of America increased their price target on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Denali Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.90.

View Our Latest Stock Analysis on DNLI

Denali Therapeutics Stock Up 3.9 %

DNLI traded up $1.01 during trading on Friday, hitting $26.97. The company’s stock had a trading volume of 290,509 shares, compared to its average volume of 1,075,732. Denali Therapeutics has a one year low of $14.56 and a one year high of $32.13. The business’s 50 day simple moving average is $27.33 and its 200-day simple moving average is $23.01. The firm has a market cap of $3.86 billion, a PE ratio of -9.59 and a beta of 1.38.

Denali Therapeutics (NASDAQ:DNLIGet Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.09. The company had revenue of $1.00 million during the quarter, compared to the consensus estimate of $10.00 million. During the same period in the prior year, the business posted $1.30 earnings per share. Denali Therapeutics’s revenue for the quarter was down 99.7% compared to the same quarter last year. Equities research analysts expect that Denali Therapeutics will post -2.53 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the sale, the director now owns 29,096 shares of the company’s stock, valued at $844,656.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the sale, the chief executive officer now directly owns 235,807 shares in the company, valued at approximately $6,529,495.83. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the transaction, the director now owns 29,096 shares of the company’s stock, valued at approximately $844,656.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. raised its stake in shares of Denali Therapeutics by 48.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after acquiring an additional 807 shares during the period. SG Americas Securities LLC bought a new stake in Denali Therapeutics in the first quarter worth about $147,000. ClariVest Asset Management LLC lifted its stake in Denali Therapeutics by 18.8% in the first quarter. ClariVest Asset Management LLC now owns 47,748 shares of the company’s stock worth $980,000 after purchasing an additional 7,568 shares during the last quarter. Swiss National Bank boosted its position in shares of Denali Therapeutics by 0.7% during the first quarter. Swiss National Bank now owns 218,200 shares of the company’s stock valued at $4,477,000 after buying an additional 1,500 shares during the period. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Denali Therapeutics during the first quarter valued at approximately $4,330,000. 92.92% of the stock is owned by institutional investors.

About Denali Therapeutics

(Get Free Report)

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

Featured Stories

Analyst Recommendations for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.